Core Viewpoint - Snap Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its advertising revenue and growth potential during the specified class period from April 29, 2025, to August 5, 2025 [1][3]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Snap securities during the class period and have until October 20, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that Snap's management created a false impression of reliable advertising revenue information while attributing uncertainties to external macroeconomic conditions [3]. Group 2: Allegations and Financial Impact - The complaint alleges that Snap's optimistic statements about advertising growth were unfounded and based on execution capabilities that the company was failing to meet [3]. - On August 5, 2025, Snap reported disappointing second quarter 2025 financial results, revealing a sharp slowdown in advertising revenue, which led to a stock price drop of more than 17% [4].

LOS ANGELES, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Charter Communications, Inc. (“Charter” or the “Company”) (NASDAQ: CHTR) common stock between July 26, 2024 and July 24, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CHARTER INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING ...

Core Viewpoint - A securities class action lawsuit has been filed against PubMatic, Inc. for failing to disclose significant changes affecting its business operations and financial outlook during the class period from February 27, 2025, to August 11, 2025 [1][2]. Group 1: Allegations and Impact - The complaint alleges that PubMatic did not inform investors about a major demand-side platform (DSP) buyer shifting clients to a new platform, which evaluates inventory differently, leading to reduced ad spend and revenue [2]. - As a result of these undisclosed issues, the positive statements made by the company regarding its business and prospects were misleading and lacked a reasonable basis [2]. - Following the release of the second quarter 2025 financial report, which acknowledged a reduction in ad spend from a top DSP partner, the company's stock price dropped by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [3][4]. Group 2: Legal Proceedings - Investors who purchased shares of PubMatic during the class period are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on October 20, 2025 [5]. - The lead plaintiff will represent the interests of other class members in the litigation process [5].

SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certai ...

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Lockheed Martin Corporation (NYSE: LMT). Shareholders who purchased shares of LMT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lockheed-martin-corporation-loss-submission-form/?id=162531&from=3  CLASS ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's lead drug candidate, deramiocel, and its FDA approval process [1][3]. Group 1: Allegations and Impact - Shareholders who purchased Capricor shares between October 9, 2024, and July 10, 2025, are encouraged to contact the firm for possible lead plaintiff appointment [1][4]. - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential FDA approval while concealing adverse facts from its Phase 2 HOPE-2 trial [3]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the Biologics License Application (BLA) due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [3]. Group 2: Next Steps for Shareholders - The deadline for shareholders to register for the class action is September 15, 2025, and there is no cost or obligation to participate [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to false or misleading statements by companies [5].

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Tesla, Inc. (NASDAQ: TSLA). Shareholders who purchased shares of TSLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/tesla-inc-loss-submission-form-2/?id=162522&from=3 CLASS PERIOD: April 19, 2023 to Jun ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Flywire Corporation regarding a class action lawsuit, encouraging those who purchased shares during the specified period to contact the firm for potential lead plaintiff appointment [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from February 28, 2024, to February 25, 2025 [3]. - Allegations include that Flywire's revenue growth was overstated, the negative impact of permit and visa-related restrictions on its business was understated, and that public statements made by the defendants were materially false and misleading [3]. Next Steps for Shareholders - Shareholders are urged to register for the class action by September 23, 2025, to participate in the case without any cost or obligation [4]. - Upon registration, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [4]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Class Action Details - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to contact the firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. Allegations Against Sarepta Therapeutics - The complaint alleges that Sarepta Therapeutics made materially false and/or misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy [3]. - Specific allegations include: - ELEVIDYS poses significant safety risks to patients [3]. - The trial protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Next Steps for Shareholders - Shareholders are advised to register for the class action by August 25, 2025, to participate in the case [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software [4]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PubMatic (PUBM) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in PubMatic between February 27, 2025 and August 11, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stoc ...